Clinical trial NCT03123887 - References

B-precursor Acute Lymphoblastic Leukemia — Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL

Citation(s)

•   Bassan R, Gatta G, Tondini C, Willemze R
  Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol. 2004 Jun;50(3):223-61. Review.
•   Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, McMillan AK, Tallman MS, Rowe JM, Goldstone AH; Medical Research Council of the United Kingdom Adult ALL Working Party
  ; Eastern Cooperative Oncology Group.. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007 Feb 1;109(3):944-50. Epub 2006 Oct 10.
•   Gökbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Hüttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
  . Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012 Sep 6;120(10):2032-41. Epub 2012 Apr 4.
•   Jabbour EJ, Faderl S, Kantarjian HM
  Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005 Nov;80(11):1517-27. Review.
•   Larson RA
  Acute lymphoblastic leukemia: older patients and newer drugs. Hematology Am Soc Hematol Educ Program. 2005:131-6.
•   Le QH, Thomas X, Ecochard R, Iwaz J, Lhéritier V, Michallet M, Fiere D
  Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program: adult acute lymphoblastic leukemia-94 trial. Cancer. 2007 May 15;109(10):2058-67.
•   Liu L, Jiao W, Zhang Y, Qu Q, Li X, Wu D
  Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Res. 2015 Mar;39(3):323-8. doi: 10.1016/j.leukres.2015.01.003. Epub 2015 Jan 16.
•   Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM; Programa Español de Tratamiento en Hematologia Group
  . Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010 Apr;95(4):589-96. doi: 10.3324/haematol.2009.014274. Epub 2010 Feb 9.
•   Pui CH, Evans WE
  Acute lymphoblastic leukemia. N Engl J Med. 1998 Aug 27;339(9):605-15. Review.
•   Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ
  Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999 Oct 1;86(7):1216-30.
•   Yan CH, Wang JZ, Liu DH, Xu LP, Chen H, Liu KY, Huang XJ
  Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. Eur J Haematol. 2013 Oct;91(4):304-14. doi: 10.1111/ejh.12168. Epub 2013 Aug 17.

A Retrospective Study to Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia(ALL)

Details for clinical trial NCT03123887